PolyMed Biopharmaceuticals Completes Pre‑A++ Funding Round Led by Caleb Capital, Fuels PROTAC‑Focused Pipeline

PolyMed Biopharmaceuticals Co., Ltd., a Chinese‑based, internationally‑oriented biopharma innovator, announced the successful closure of its Pre‑A++ financing round. The deal was led by Caleb Capital and raised an undisclosed yet substantial amount of capital earmarked for accelerating the clinical development of its advanced drug pipeline.

Company Profile

• Headquarters & Global Presence – Based in Hangzhou with satellite offices in Shanghai and Boston.
• Therapeutic Focus – Cancer, autoimmune disorders, and inflammation‑related diseases.
• Technology Edge – Combines Artificial Intelligence, structural biology, and proteomics to tackle “difficult‑to‑drug” targets through bifunctional molecules such as PROTACs and Antibody‑Drug Degraders.

Pipeline Highlights

HPB‑143 – IRAK4‑Targeting PROTAC

• Mechanism – Induces selective degradation of IRAK4, a key driver of inflammation and oncogenesis.
• Clinical‑Stage Advantages – Superior degradation potency, high oral bioavailability, and robust efficacy in pre‑clinical models.
• Licensing & Revenue Potential – Rights outside Greater China & Southeast Asia were licensed to Photys Therapeutics (Boston) in February 2025, yielding an upfront payment, share equity, and up to USD 300 million in milestone payments plus sales royalties.

HPB‑092 – FLT3/IRAK4 Dual‑Target Inhibitor

• Target Profile – Simultaneous inhibition of FLT3 (common AML driver) and IRAK4.
• Safety & Efficacy – Designed for a broader AML patient population with a superior safety margin compared to existing FLT3 inhibitors.
• Clinical Outlook – Expected to deliver more durable responses in acute myeloid leukemia (AML) patients.

Strategic Impact of the Funding

• Accelerated Clinical Development – Capital will support GMP manufacturing, IND filings, and pivotal Phase I/II trials for both HPB‑143 and HPB‑092.
• Technology Scale‑Up – Enables expansion of AI‑driven lead‑optimization pipelines and proteomic screening platforms.
• Market Positioning – Strengthens PolyMed’s standing as a leader in PROTAC‑based therapeutics and positions the company for future licensing or partnership opportunities.

Forward‑Looking Statements

This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech